Pre-Conference Workshop Day

Tuesday 25th February 2025

8:00 am
Morning Check In & Light Refreshments

9:00 am
Workshop A

Creating the ‘Ideal’ Radiopharmaceutical: Considerations for the Drug Design Toolbox

Synopsis

Delve into a holistic overview of the art of novel radiopharmaceutical drug design. With cutting-edge progress expanding the tools used in novel radiopharmaceutical drug development there is a great number of options to optimize the chemistry of your molecule. From targeting moiety, linker, chelator and payload – what are the considerations when approaching drug design and does an ‘ideal’ radiopharmaceutical truly exist?

Join this interactive discussion-based session to explore questions on:

  • Considering what is the best starting point when developing a drug: targeting strategy or payload led?
  • Exploring isotope agnostic approaches
  • Understanding disease biology to create the optimal strategy for drug design
  • Exploring toxicities and how to avoid them in varying modalities

12:00 pm
Lunch & Networking

1:00 pm
Workshop B

Assessing Radiopharmaceutical Pharmacokinetics: Tools & Technologies

Synopsis

Traditional small molecule drug development has well established assays, tools and

technologies for preclinical research, but in the evolving world of radiopharmaceuticals

specialised tools are required.

Delve into this workshop to explore:

  • Preclinical Imaging for PK Evaluation: Discover how small-animal PET, SPECT, and MRI are utilized in preclinical models to visualize and quantify radiopharmaceutical biodistribution, uptake, and clearance, providing crucial pharmacokinetic data early in drug development
  • AI-Driven Data Analysis for PK Prediction: Explore how machine learning algorithms analyze large datasets from preclinical and clinical studies to predict pharmacokinetic behavior, improving the accuracy of drug distribution, metabolism, and clearance models in radiopharmaceuticals
  • Ex Vivo Analysis and Blood Sampling Techniques: Explore tools such as ex vivo tissue analysis, autoradiography, and frequent blood sampling in preclinical models to measure radiopharmaceutical distribution and metabolism, ensuring comprehensive PK profiling